Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial

Journal of the American College of Cardiology

Volumn 32, Issue 7, 1998, Pages 2003-2010

  Harrington, R A ^a   Van de Werf, F ^a   Luyten, A ^a   Potkin, B ^a   McIntosh Yellin, N ^a   Morgan, C ^a   Feskiw, K ^a   Finnie, K ^a   McCreery, S ^a   Diodati, J ^a   Shalit, E ^a   Roth, S ^a   Smith, J ^a   Hui, W ^a   Kvill, L ^a   Senaratne, M ^a   Goeres, M ^a   Greenwood, P ^a   Prosser, A ^a   Kristinsson, A ^a   Runarsdottir, V ^a   Oddsson, G ^a   Plardardottir, H ^a   Chandler, A B ^a   Edwards, M ^a   Becker, J ^a   Nallcy, S ^a   Becker, R ^a   Ball, S ^a   Bates, E ^a   Johnson, T ^a   Harrington, R ^a,a   Quintero, K ^a   Paraschos, A ^a   Paraschos, L ^a   Lerrick, K ^a   Spinogatti, B ^a   Bhalodkar, N ^a   Valeria, A ^a   Moliterno, D ^a,a   Desantis, P ^a   White, J K ^a   Andreatta, K ^a   Burks, J ^a   Kohler, N ^a   Seaworth, J ^a   Jensen, J ^a   Carreon, G ^a   Nygaard, T ^a   White, J ^a   Puma, J ^a   Jones, L ^a   Armstrong, P ^a   Sutherland, W ^a   Topol, E ^a   Califf, R ^a   Newby, K ^a   Peek, M ^a   Binanay, C ^a   Tinnin, K ^a   Bhapkar, M ^a   Dorsey, M ^a   Parker, J ^a   Tardiff, B ^a   Alexander, J ^a   Crenshaw, B ^a   Green, C ^a,a   Strand, G ^a   Krucoff, M ^a   Trollinger, K ^a   Ellis, S ^a   Ivanc, T ^a   Debowey, D ^a   Hillegass, W ^a   Lincoff, M ^a   Tcheng, J ^a   Rames, A ^a   Steiner, B ^a   Bokslag, M ^a   Marcantuono, D ^a   Luiden, E ^a   Nielsen, T ^a   more..

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; LAMIFIBAN; PLACEBO; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANGIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; ELECTROCARDIOGRAM; FIBRINOLYSIS; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REPERFUSION; ST SEGMENT; THROMBOCYTE AGGREGATION;

ACETATES; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; TYROSINE;

EID: 0032420213     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00474-4     Document Type: Article

References (32)

1. Lincoff A.M., Topol E.J., Sigmon K.N., et al. Is a coronary artery with TIMI grade 2 flow "patent"? Outcome in the thrombolysis and angioplasty in myocardial infarction trials. Am J Cardiol. 75:1995;871-876.
2. Anderson J.L., Karagounis L.A., Becker L.C., Sorensen S.G., Menlove R.L. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 study . Circ Res. 87:1993;1829-1839.
3. Lincoff A.M., Topol E.J. Illusion of reperfusion does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 88:1993;1361-1374.
4. Coller B.S. Platelets and thrombolytic therapy. N Engl J Med. 322:1990;33-42.
5. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction ISIS-2 . Lancet. ii:1988;349-360.
6. Alexander J.H., Harrington R.A. Adjunctive antiplatelet therapy in acute myocardial infarction the road to improved infarct-related artery patency . J Thromb Thrombol. 4:1997;353-355.
7. Lefkovits J., Plow E.F., Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 332:1995;1553-1559.
8. Coller B.S. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation. 92:1995;2373-2380.
9. Tan H.C., Harrington R.A., Tcheng J.E. Platelet glycoprotein IIb/IIIa integrin blockade in coronary artery disease current state of the art . J Thromb Thrombol. 4:1997;431-439.
10. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
11. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
12. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE study . Lancet. 349:1997;1429-1435.
13. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II . Lancet. 349:1997;1422-1428.
14. Ferguson J.J. EPILOG and CAPTURE trials halted because of positive interim results. Circulation. 93:1996;637.
15. Combined accelerated tissue plasminogen activator and platelet glycoprotein IIb/IIIa integrin blockade with Integrilin(TM) in acute myocardial infarction results from a randomized, placebo-controlled, dose-ranging trial . Circulation. 95:1997;846-854.
16. Kleiman N.S., Ohman E.M., Califf R.M., et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 fab following thrombolytic therapy results of the TAMI 8 pilot study . J Am Coll Cardiol. 22:1993;381-389.
17. Kouns W.C., Kirchhofer D., Hadvary P., et al. Reversible conformational changes induced in glycoprotein IIb/IIIa by a potent and selective peptidomimetic inhibitor. Blood. 80:1992;2539-2547.
18. Theroux P., Kouz S., Roy L., et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina - the Canadian lamifiban study. Circulation. 94:1996;899-905.
19. Randomized, placebo-controlled study of lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction rationale and design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) study . J Thromb Thrombol. 2:1995;165-169.
20. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
21. Krucoff M.W., Croll M.A., Pope J.E., et al. Heuristic and logistic principles of ST-segment interpretation in the time domain. Evolution in the context of the TAMI 7 trial design. J Electrocardiol. 23:(Suppl):1990;6-10.
22. Krucoff M.W., Wagner N.B., Pope J.E., et al. The portable programmable microprocessor-driven real-time 12-lead electrocardiographic monitor a preliminary report of a new device for the noninvasive detection of successful reperfusion or silent coronary reocclusion . Am J Cardiol. 65:1990;143-148.
23. Krucoff M.W., Croll M.A., Pope J.E., et al. Continuously updated 12-lead ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographic observations. Am J Cardiol. 71:1993;145-151.
24. Harrington RA, Kleiman NS, Granger CB, Ohman EM, Scarborough RM, Berkowitz SD. Relationship between inhibition of platelet aggregation and clinical outcomes. Am Heart J (in press).
25. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 329:1993;1615-1622.
26. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion importance of early and complete infarct artery reperfusion . Circulation. 91:1995;1923-1928.
27. Tcheng J.E., Ellis S.G., George B.S., et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody fab 7E3 in high-risk coronary angioplasty. Circulation. 90:1994;1757-1764.
28. An international, randomized, controlled trial of lamifiban, a platelet glycoprotein IIb/IIIa inhibitor, heparin, or both in unstable angina. Circulation. 97:1998;2386-2395.
29. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 90:1994;1631-1637.
30. Antman E.M. Hirudin in acute myocardial infarction - thrombolysis and thrombin in myocardial infarction (TIMI) 9B trial. Circulation. 94:1996;911-921.
31. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 335:1996;775-782.
32. Perspectives on large scale cardiovascular clinical trials for the new millenium. Circulation. 95:1997;1072-1082.